MedWatch

ALK's house dust mite tablet approved in Canada

The Danish allergy group ALK-Abello has gotten the Canadian authorities’ permission to market the company’s most promising medicine, the house dust mite (HDM) allergy tablet Acarizax.

ALK’s Executive Vice President, Research and Development, Henrik Jacobi.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles